CD31 expression on peripheral blood stem cells predicts both early neutrophil and platelet engraftments

Basit Öğe Kaydı
dc.contributor.authorDonmez, Ayhan
dc.contributor.authorTombuloglu, Murat
dc.contributor.authorGulbahar, Okan
dc.contributor.authorArik, Bahar
dc.contributor.authorCagirgan, Seckin
dc.contributor.authorVural, Filiz
dc.contributor.authorGokmen, Nihal
dc.date.accessioned2019-10-27T22:07:45Z
dc.date.available2019-10-27T22:07:45Z
dc.date.issued2013
dc.departmentEge Üniversitesien_US
dc.description.abstractNo detailed information currently exists about the immune phenotypic profiles of peripheral blood stem cells (PBSCs) obtained by different mobilization regimens. The effects of these profiles on the outcome of transplantation are largely unknown. In this prospective study, the surface immune phenotypic features (CD11a, CD18, CD31, CD38, CD44, CD62e, CD62L, CD90, CD117, CD135 and CD184 expression) of sorted PBSCs that had been mobilized by growth factor with (group I and group II) or without (group III) disease-specific chemotherapies were investigated. The immune phenotypic features on mobilized PBSCs in groups I, II and III were not significantly different. The CD31 (platelet endothelial cell adhesion molecule-1) positivity ratio on PBSCs inversely correlated with both the duration of neutrophil (r = -0.32, p = 0.03) and platelet (r = -0.36, p = 0.02) engraftment. No relationship was found between the engraftment (neutrophil and platelet) durations and CD184 (chemokine receptor CXC motif receptor 4 [CXCR4]) expression on PBSCs. We demonstrated that the surface immune phenotypic profiles on PBSCs obtained by several mobilization regimens were not different. To our knowledge, this is the first study to demonstrate that CD31 expression on human PBSCs may positively affect both neutrophil and platelet engraftment. Contrary to our expectations, CD184 (CXCR4) expression on PBSCs has no effect on neutrophil or platelet engraftment. Considered together, our results suggest that additional surface antigens (such as CD31) may be more effective in the homing process. (C) 2013 Elsevier Ltd. All rights reserved.en_US
dc.description.sponsorshipEge UniversityEge University [06-TIP-002]; Ege University Research Ethics CommitteeEge University [06-8/17]en_US
dc.description.sponsorshipThis project was supported by an Ege University Grant (06-TIP-002, Ege University Research Ethics Committee Decision Number: 06-8/17).en_US
dc.identifier.doi10.1016/j.transci.2013.08.006en_US
dc.identifier.endpage312en_US
dc.identifier.issn1473-0502
dc.identifier.issue2en_US
dc.identifier.pmid24025427en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage307en_US
dc.identifier.urihttps://doi.org/10.1016/j.transci.2013.08.006
dc.identifier.urihttps://hdl.handle.net/11454/49069
dc.identifier.volume49en_US
dc.identifier.wosWOS:000327172600041en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherPergamon-Elsevier Science Ltden_US
dc.relation.ispartofTransfusion and Apheresis Scienceen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectPeripheral blood stem cellsen_US
dc.subjectMobilizationen_US
dc.subjectHomingen_US
dc.subjectCD31en_US
dc.subjectCXCR4en_US
dc.titleCD31 expression on peripheral blood stem cells predicts both early neutrophil and platelet engraftmentsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu